Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27.
Ann Neurol. 2021.
PMID: 33586143
Free PMC article.
Clinical Trial.
We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety and efficacy. ...Safety and efficacy data from PREVENT and its OLE (interim data cut, July 31, 2019) were combined for this analysis. …
We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety a …
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Storm MRO, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, Schaug JP, Darling Rasmussen P, Huus CL, Zwi M, Kirubakaran R, Simonsen E, Gluud C.
Storebø OJ, et al.
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. doi: 10.1002/14651858.CD009885.pub3.
Cochrane Database Syst Rev. 2023.
PMID: 36971690
Free PMC article.
Review.
Item in Clipboard
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL, Murray-Petzold C, Collins MH, Abonia JP, Bolton SM, DiTommaso LA, Martin LJ, Zhang X, Mukkada VA, Putnam PE, Kellner ES, Devonshire AL, Schwartz JT, Kunnathur VA, Rosenberg CE, Lyles JL, Shoda T, Klion AD, Rothenberg ME.
Kliewer KL, et al.
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):803-815. doi: 10.1016/S2468-1253(23)00145-0. Epub 2023 Jun 16.
Lancet Gastroenterol Hepatol. 2023.
PMID: 37336228
Clinical Trial.
After the 12-week double-blind period, patients were eligible for entry into two open-label extension (OLE) periods up to week 88, in which all patients received benralizumab. ...Two patients had serious adverse events (dizziness and rhabdomyolysis in one patient; aspirati …
After the 12-week double-blind period, patients were eligible for entry into two open-label extension (OLE) periods up to week 88, in …
Item in Clipboard
Cite
Cite